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Conclusions: This analysis showed a MDC with a statistically 
significant advantage in favor of sequence A for both CTV and nodal 
subvolumes. Nevertheless, MDC in sequence B for CTV and subvolume 
1 were close to 0.80 and therefore clinically reliable, with a time 
sparing of 93%. Final analysis will confirm the clinical reliability and 
feasibility of the system and the total time sparing for both the 
Delineator and the Reviewer. 
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Purpose/Objective: Positron emission tomography (PET) with [18F]-
fluoromisonidazole (FMISO), a tracer of hypoxia, is particularly useful 
in radiotherapy with potential dose escalation on hypoxic subvolumes. 
However, the definition of FMISO volumes remains problematic due to 
the low contrast of the images and the absence of consensus about 
the segmentation methods.  
Materials and Methods: The aim of this methodological study about 
the use of FMISO PET for radiotherapy planning is to determine the 
best timing for acquisitions and to study different volume 
segmentation methods. For this purpose, 15 patients with head and 
neck suamous cell carcinomas (HNSCC) underwent FMISO-
PET/Computed tomography (CT) with several acquisitions at 2, 3 and 
4 hours after injection of the tracer and three different automatic 
segmentation methods of PET volumes were tested. The first method 
was a fixed thresholding, the FMISO volume being defined by all voxels 
having an activity ≥ 1.4 of the activity of the background (AB). The 
second method was an adaptive thresholding based on the ratio 
between the maximum tumour activity (AT) and AB (RT/B). The third 
method was a stochastic algorithm, the fuzzy locally adaptive 
Bayesian (FLAB) method. Tumour volumes were also manually 
delineated on the CT images by the radiation oncologist. 
Results: For one patient, no hypoxia was observed. For eight patients, 
hypoxia was observed in the primary tumour and nodes, for two in the 
primary tumour only and for four in the nodes only. The calculated 
mean RT/B was 2.5 (range 1.7-2.9), 3.1 (range 2-4.5) and 3.4 (range 
2.3-6.1) for images aqcuired at 2, 3 and 4 hours respectively. It 
appears that the best contrast is obtained on the 4 hour-acquisition. 
At 4 hours, the mean FMISO volumes were 18.9 cc (range 0.1-81) with 
the fixed threshold, 9.5 cc (range 0.9-33.1) with the adaptive 
threshold and 12.5 cc (range 0.9-38.4) with the FLAB method. The 
volumes defined with the adaptive threshold were also the smallest. 
The fixed threshold led to larger volumes (199% of the adaptive 
volumes) and the FLAB volumes were intermediate (132% of the 
adaptive volumes). CT volumes were much larger with a mean of 39.1 
cc (range 1.2-116) corresponding to a value more than 4 times larger 
than the FMISO adaptive volume.  
Conclusions: Compared to CT imaging, FMISO PET imaging in HNSCC 
enables to define restricted volumes, on which a potential increase of 
the radiation dose is possible. For a radiotherapy application, images 
must be acquired 4 hours after injection to provide a better contrast. 
Adaptive or stochastic methods are more appropriate to FMISO volume 
segmentation. Indeed, FMISO images are low contrasted and fixed 
thresholding leads to overestimated volumes. However, because of 
the lack of published data, additional work is required before using 
FMISO PET to guide dose painting in intensity modulated radiotherapy. 
   
PO-0754  
Stereotactic radiotherapy of liver metastases: 4DCT treatment 
planning and MRI follow-up on normal tissue response 
C. Petersen1, T. Frenzel1, A. Koops2, A. Krüll1, M. Todorovic1, R. 
Werner3, T. Gauer1 
1University Medical Center Hamburg - Eppendorf (UKE), Department 
of Radiation Oncology, Hamburg, Germany  
2University Medical Center Hamburg - Eppendorf (UKE), Department 
of Diagnostic and Interventional Radiology, Hamburg, Germany  
3University of Lübeck, Institute of Medical Informatics, Lübeck, 
Germany  
 
Purpose/Objective: SBRT is increasingly considered an alternative to 
surgical resection of liver metastasis or liver related cancers. Our 
clinical workflow consists of precise target localization; analysis of 
tumor motion due to respiration; highly conformal dose distribution; 
and image-guidance at the time of dose delivery. Tumor and normal 
tissue reponse is monitored through morphological changes by MRI. 
Quantitative in vivo data of the hepatic tolerance to irradiation is very 
limited. However, such knowledge is essential for the treatment 
strategy in patients with multiple or large tumors or in situations with 
a small parenchymal reserve after liver resection. In a feasibility study 
for further healthy liver sparing, four consecutive patients with liver 
lesions were retrospectively evaluated. 
Materials and Methods: Clincal cases consist of (1) solitary 
metastases/breast cancer; (2) four metastases/cholangiocellular 
carcinoma; (3) R1-resected gallbladder cancer; (4) multiple 
metastasis/bladder cancer. For all patients a 4D-CT scan was 
performed. GTV contours of the single calculated respiratory phases 
(10 in total) were transfered to the average CT of the 4D-CT data to 
generate the ITV. Highly conformal dose coverage was achieved by 
Varian VMAT using 6 MV photons. Dose prescription ranged from 5 x 7 
Gy (60% isodose surrounding the PTV) to 25 x 1.8 Gy (ICRU). MRI was 
carried out before and 6 weeks/3 month after therapy. MR-sequences 
were conducted with T1-w GRE enhanced by hepatocyte-targeted Gd-
EOB-DTPA. MRI data sets were merged with the planning CT including 
the dose distribution. Reviewers indicated the border of hypointensity 
on T1-w images (loss of hepatocyte function) or hyperintensity on T2-
w images (edema). The potential of healthy liver sparing was 
estimated by the treshold dose for these morphological changes. 
Results: Analysis of the 4D-CT data resulted in a mean target motion 
from 5 to 9 mm in magnitude. Kilo-voltage CBCT scans were created 
before each fraction to verify and adjust the target localization. 
Image fusion of the average treatment planning CT and kV-CBCT scans 
resulted in patient repositioning in a maximum of 6 mm magnitude 
per fraction. The dose to the liver was within accepted guidelines 
(700 ml healthy liver receiving less than 15 Gy). The minimum dose 
resulting in visible signal intensity changes (edema/loss of hepatocyte 
function) was approximately 20 Gy (Fig. 1). Depending on the number, 
size and location of the metastases and the healthy liver volume, the 
remaining healthy volume (excluding the 20 Gy liver subvolume) 
measures from 10 to 40%. 
 
  
Conclusions: In SBRT of liver metastases, 4D-CT data is required for 
target motion management and treatment planning. In this 
preliminary retrospective evaluation, a threshold dose of 
approximately 20 Gy inducing focal loss of liver function was detected 
after 4 weeks by MRI. Further investigation is warranted to assess the 
correlation between morphological changes in the mean dose 
exposure to the liver and clinical outcome.  
  
